December 19, 2005 – The stock of pharma giant Pfizer moved higher after a US court ruling blocked generic atorvastatin until 2011. Atorvastatin or Lipitor is Pfizer’s and the world’s best selling prescription drug with almost $12 billion in annual sales. The drug is key to Pfizer’s continuing success, at least in the short term, representing almost a quarter of Pfizer’s earnings. The ruling was issued on Friday against Ranbaxy Laboratories of India. A little over a year ago, we reported on the strength of Pfizer’s pipeline. Apparently others are now starting to take notice. We look at near-to-midterm potential for this stock...
